NCT01991184View on ClinicalTrials.gov

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
Interventions
DRUG

GDC-0853

Multiple escalating doses

Trial Locations (10)

3002

Peter MacCallum Cancer Centre; Department of Haematology, Melbourne

4102

Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba

6009

Linear Clinical Research Limited, Nedlands

37203

Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville

43212

The Ohio State University Wexner Medical Center, Columbus

63110

Washington University School of Medicine, St Louis

97239

Oregon Health Sciences Uni, Portland

98109

Seattle Cancer Care Alliance, Seattle

94305-5820

Stanford Cancer Center, Stanford

97401-8122

Willamette Valley Cancer Ctr - 520 Country Club, Eugene

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY